The company Bosnalijek increased its revenues in the first quarter of this year but once again operated at a loss.
The largest domestic pharmaceutical company had total revenues of 26.6 million BAM in the first three months, compared to about 20 million from the same period last year.
Revenue from customer contracts increased from 19.4 to 24.4 million BAM.
Expenses also increased from 27.2 million to 31.5 million BAM.
The first quarter ended with a loss of approximately 5 million BAM. The loss in the same quarter last year was 7.2 million BAM.
However, the company ended last year with a profit of 11.5 million BAM, and the year before that with a profit of 13.8 million BAM.
